Lianpeng Chang

Lianpeng Chang

Auto-generated profile, based on publicly available information

Lianpeng Chang

GenePlus-Beijing, Beijing, P.R. China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Fei MaFei Ma
Fei Ma
YGYanfang Guan
Yanfang Guan
ZYZongbi Yi
Zongbi Yi
LCLianpeng Chang
Lianpeng Chang
QLQiao Li
Qiao Li
BXBingHe Xu
BingHe Xu

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RJRu Jia
Ru Jia
PLPansong Li
Pansong Li
CZChuanhua Zhao
Chuanhua Zhao
YWYan Wang
Yan Wang
RLRongrui Liu
Rongrui Liu
JXJianming Xu
Jianming Xu
E16053Background: Esophageal squamous cell carcinoma (ESCC) is one of the most malignant tumors with high mortality. Radiation therapy (RT) is currently one of the main treatments to ESCC. Circulating tumor DNA (ctDNA) in peripheral blood, containing tumor genetic alteration information, has been confirmed a potential noninvasive biomarker for various cancer types. Therefore, we investigated the clinical implications of ctDNA in ESCC patients receiving RT. Methods: Locally advanced ESCC patients who underwent radical RT from July 2013 to May 2016 were enrolled. Serial plasma samples were collected pre- and post-RT at every visit until recurrence or metastasis, and used for cell-free DNA (cfDNA) extraction. A customized panel of 180 genes was designed including ESCC common driver genes. Next-generation sequencing (NGS) was performed to identify somatic mutations and mutation spectrum pre- and post-RT was compared. Results: Sixty-seven baseline and postradiation plasma samples were collected from 24 ESCC pa...

31 March 2023
Verified
Other
Open access
XAXinghao Ai
Xinghao Ai
JCJiuwei Cui
Jiuwei Cui
JZJiexia Zhang
Jiexia Zhang
RCRongrong Chen
Rongrong Chen
WLWen Lin
Wen Lin
Shun LuShun Lu
Shun Lu
Purpose:Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers is not always applicable. This prospective clinical trial was to investigate whether paired tissue and circulating tumor DNA (ctDNA) could describe the clonal architecture of advanced non–small cell lung cancer (NSCLC) and its association with clinical outcome (NCT03059641).Patients and Methods:Paired tumor and plasma ctDNA samples were sequenced by target-capture deep sequencing of 1,021 genes. Clonal dominance analysis was performed on the basis of PyClone.Results:Overall, 300 treatment-naïve patients with stage IIIB–IV NSCLC were recruited from 14 centers. Of the 94 patients with available ctDNA data for EGFR clonal architecture analysis, 72 (76.6%) showed EGFR as the dominant clone. The median progression-free survival was longer for these patients than for the 22 patients whose EGFR was nondominant clone [11 vs. 10 months; HR, 0.46; 95% confidence interval (CI), 0.24–0.88; P = 0.02]. The difference was more significant if both tissue and ctDNA defined EGFR as dominant clone (n = 43) versus those not (n = 8; 11 vs. 6 months; HR, 0.13; 95% CI, 0.04–0.50; P = 0.003). Moreover, multivariate Cox proportional HR analysis demonstrated EGFR clonal architecture as an independent prognostic indicator of the efficacy of EGFR-tyrosine kinase inhibitors (TKIs).Conclusions:Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer. EGFR mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs in NSCLC.


20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YLYi Li
Yi Li
CCChuanben Chen
Chuanben Chen
Yu ChenYu Chen
Yu Chen
YGYan-Fang Guan
Yan-Fang Guan
YHYingying Huang
Yingying Huang
XYXin Yi
Xin Yi
E15250 Background: Predictive biomarkers of response to immune checkpoint inhibitors (ICIs) help to identify cancer patients who will benefit from immunotherapy. PRKDC is an important gene relates to DNA double-strand break (DSB) repair and central T-cell tolerance. We aim to investigate the association between PRKDC mutations and tumor mutation burden (TMB), tumor microenvironments (TME), and response to ICIs. Methods: The whole exome sequencing data of 4022 solid tumor samples from the Cancer Genome Atlas (TCGA) and the panel-based sequencing data of 4652 solid tumor samples from GenePlus-Beijing, China were used to analyze TMB. The mRNA expression data of 3541 solid tumor samples from TCGA was used to explore the effect of PRKDC mutation on TME. Four ICIs-treated cohorts were analyzed for verifying the correlation between PRKDC mutation and the response to ICIs. Results: In TCGA datasets and GenePlus datasets, we both found that the TMB in PRKDC mutation samples were significantly higher than PRKDC wild-type samples(P < 0.05, P 0.05). Further, in TCGA datasets, it showed that PRKDC mutation samples were associated with significant expression increase of CD8+ T cells, NK cells, immune-checkpoint, chemokines etc compared to PRKDC wild-type samples (P < 0.05). In ICIs-treated cohorts, we also found the PRKDC mutation was associated with superior survival(median PFS, not reached (NR) vs. 6.8 months HR, 0.2893 95% CI, 0.1255-0.6672 P = 0.0650, Hellmann cohort; median OS, 1184 days vs. 250 days HR, 0.5126 95% CI, 0.2715-0.9679 P = 0.1020, Allen cohort), and the superiority was significantly in multivariate Cox regression analyses (HR, 0.361 95% CI,0.155-0.841; P = 0.018, Allen cohort; HR, 0.240 95% CI,0.058-0.998; P = 0.050, Hellmann cohort). Conclusions: PRKDC mutations are associated with an increased TMB, an inflamed TME and a better response to ICIs, it may be a potential predictive biomarker for ICIs-immunotherapy.